Q-omics provides the consensus-scored PLB1 profile across patient tissues and cancer cell-line models. PLB1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PLB1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PLB1 RNA expression shows 17,521 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where PLB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLB1 survival associations across molecular data types. PLB1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLB1 RNA expression–survival associations across cancer types. High PLB1 expression shows unfavorable associations in ACC, STAD, LGG, KIRC and OV, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PLB1 RNA expression.
This table summarizes PLB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PLB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLB1 shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRC, HNSC, LUAD and KIRP. The KIRC box plot shows higher PLB1 RNA expression in tumor versus normal tissue (log2 FC = +0.861, t-test p < 0.001).
This table shows molecular features associated with PLB1 in patient tissues and cancer cell lines. In patient samples, PLB1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
